Companies
- Companies
- Company details
Acceleron Pharma
Out-licensing
ACE-011, A Protein Therapeutic based on the Activin Receptor Type IIA (ActRIIA): ACE-011 is Currently in Phase II Clinical Trials for Treatment of Myeloma Bone Disease More
ACE-031, A Protein Therapeutic based on the Activin Receptor Type IIB (ActRIIB): Phase I Clinical Development for Treating Muscle Loss More
Preclinical Development of ACE-04: A Novel Inhibitor of Multiple Mediators of Angiogenesis More
R&D
To view this information, you must subscribe to Pharmalicensing Intelligence.
Senior management
To view this information, you must subscribe to Pharmalicensing Intelligence.
Board of directors
To view this information, you must subscribe to Pharmalicensing Intelligence.
Related Reports
Market Research Reports provided by reports.iptechex.com
Apr 2011 - 42 pages - $500
Nov 2010 - 50 pages - $500
Jul 2010 - 43 pages - $750
Nov 2010 - 90 pages - $600
Dec 2010 - 12 pages - $99
Nov 2010 - 15 pages - $99
Sep 2010 - 14 pages - $99
Apr 2011 - 5 pages - $100
Aug 2010 - 25 pages - $99
Apr 2010 - 23 pages - $99
Contact details
Jonathan Yu
Head office
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us